» Articles » PMID: 1846369

Analogues of Parathyroid Hormone Modified at Positions 3 and 6. Effects on Receptor Binding and Activation of Adenylyl Cyclase in Kidney and Bone

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1991 Jan 25
PMID 1846369
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Predictive and spectroscopic methods were used to develop a model of the structures of the 1-34 peptides of parathyroid hormone (PTH) and the PTH-related protein (PTHrP). Circular dichroism (CD) studies of bovine PTH-(1-34) and human PTHrP-(1-34)amide in the presence of trifluoroethanol suggest the presence of 24-26 alpha-helical residues. For both peptides, interactions between amino- and carboxyl-region alpha-helices are predicted to result in a hydrophobic core with externally facing hydrophilic residues that include probable determinants of receptor binding and activation. Two such residues, Ser3 and Gln6, are conserved in all known members of the PTH/PTHrP family. We have synthesized 13 novel analogues of bovine PTH-(1-34) monosubstituted at positions 3 and 6 and have determined their biological activities in renal and bone cell radioreceptor and adenylyl cyclase assays. Position 3 analogues displayed biological activity that was reduced in direct proportion to the volume of the substituent side-chain. Position 6 analogues also displayed reduced biological activity, but no simple correlation with side-chain volume or hydrophobicity was evident. The analogues fully displaced labeled PTH from binding sites in renal membranes and bone cells, but [Phe3]bPTH-(1-34), [Tyr3]bPTH-(1-34), [Phe6] bPTH-(1-34), and [Ser6]bPTH-(1-34) were only partial agonists in one or both adenylyl cyclase assays. Of these, [Phe3]bPTH-(1-34) and [Phe6]bPTH-(1-34) were tested for antagonist activity and were found to inhibit the activation of adenylyl cyclase in response to bPTH-(1-34) or hPTHrP-(1-34)amide. These results indicate that positions 3 and 6 contribute important determinants of PTH receptor binding and activation. Modification at these positions represents a novel approach to the development of antagonists of PTH action.

Citing Articles

Comparative Physicochemical and Biological Characterisation of the Similar Biological Medicinal Product Teriparatide and Its Reference Medicinal Product.

Kovacs P, Schafer T, Hada V, Hever H, Klingelhofer S, Nebel M BioDrugs. 2019; 34(1):65-75.

PMID: 31595483 PMC: 6985066. DOI: 10.1007/s40259-019-00386-x.


Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex.

Hwang S, Seo D, Byun Y, Park J Int J Nanomedicine. 2016; 11:4231-46.

PMID: 27621618 PMC: 5012625. DOI: 10.2147/IJN.S110573.


Parathyroid hormone is a heparin/polyanion binding protein: binding energetics and structure modification.

Kamerzell T, Joshi S, McClean D, Peplinskie L, Toney K, Papac D Protein Sci. 2007; 16(6):1193-203.

PMID: 17525467 PMC: 2206658. DOI: 10.1110/ps.062613807.


Interaction of PTH and PTHrP with their receptors.

Gardella T, Juppner H Rev Endocr Metab Disord. 2001; 1(4):317-29.

PMID: 11706746 DOI: 10.1023/a:1026522619828.


Subtle differences in the mitogenic effects of recombinant human bone morphogenetic proteins -2 to -7 on DNA synthesis on primary bone-forming cells and identification of BMP-2/4 receptor.

Mayer H, Scutt A, Ankenbauer T Calcif Tissue Int. 1996; 58(4):249-55.

PMID: 8661956 DOI: 10.1007/BF02508644.